News

A noninvasive MRI-based approach may help assess disease severity and predict the likelihood of serious complications in people with primary sclerosing cholangitis (PSC), a…

A global clinical trial testing Mirum Pharmaceuticals’ oral therapy maralixibat in people with itching, or pruritus, due to rare cholestatic conditions has finished…

Sagimet Biosciences said it expects a clinical trial testing a combination therapy in people with cirrhosis, or irreversible liver scarring, due to metabolic dysfunction-associated steatohepatitis…

A new artificial intelligence (AI)-based model that combines information from imaging scans and blood levels of a protein called matrix metalloproteinase-7 (MMP-7) may aid in…

A late-stage clinical trial assessing the safety and effectiveness of Mirum Pharmaceuticals’ brelovitug for adults with chronic hepatitis D has completed enrollment, and…

Hispanic people with primary biliary cholangitis (PBC) are significantly less likely to achieve complete lab-based remission — defined as a normalization of the liver damage…

Long-term exposure to particles produced from cooking grilled meat can trigger liver damage and cholestasis — slowing or stalling of the digestive fluid bile…

The first participant has been dosed in a large clinical trial testing TGM-312, a novel gene-silencing therapy designed to slow the progression of metabolic dysfunction-associated…

Children with Alagille syndrome who have lower blood levels of bile acids, the main component of the digestive fluid bile, have better long-term liver…

In preclinical studies, AT-587, Atea Pharmaceuticals’ lead oral candidate for treating hepatitis E, showed potent antiviral activity against multiple strains of the hepatitis…